Epizyme to Present at Upcoming Conferences in September
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in five upcoming conferences in September:
“Oncology Drug Development: First-In-Class vs. Best-In-Class vs. Good Enough?”
- Citi 9th Annual Biotech Conference at the Mandarin Oriental Boston on Wednesday, September 3. Epizyme Chief Executive Officer Robert Gould, Ph.D., will participate in a panel titled “Novel Therapies for Blood Disorders: Making Big Strides vs. Baby Steps” at 2 p.m. ET.
- JMP Securities Boston Biotechnology Day at the Langham on Friday, September 5. Epizyme leadership will participate in a fireside chat presentation at 10 a.m. ET.
- Rodman & Renshaw 16th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., at the New York Palace Hotel on Tuesday, September 9. Epizyme leadership will present a company overview at 3:20 p.m. ET. A live webcast will be available on the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company’s website for 30 days after the conference.
- Innovation Connecting Conference at the Parc Des Expositions, Toulouse, France on Wednesday, September 17. Epizyme Chief Scientific Officer Robert Copeland, Ph.D., will participate in a panel titled “The Future Biotechnologies – Round Table” at 3:15 p.m. CET.
- Cancer Advance at Harvard Medical School on Tuesday, September 30. Epizyme President and Chief Financial Officer Jason Rhodes will participate in a panel titled “Oncology Drug Development: First-In-Class vs. Best-In-Class vs. Good Enough?” at 8:30 a.m. ET.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.